可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]刘佳顺,任澎.心房颤动的分子生物学机制研究进展[J].心脏杂志,2010,22(3):453-455.
[2]杨阳,杨新莉.心房颤动的易发因素及其机机制研究[J].心脏杂志,2005,17(5):493-494.
[3]Thomas M,Dublin S,Kaplan RC,et al.Blood pressure control and risk of incident atrial fibrillation[J]. Am J Hypertens,2008,21(10):1111-1116.
[4]Curtis AB,Gersh BJ,Corley SD,et al.Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management(AFFIRM)study[J]. Am Heart J,2005,149(4):645-649.
[5]Wachtell K,Lehto M,Gerdts E,et al.Angiotensin II receptor blockade reduces new-onset atrial?brillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension(LIFE) study[J].J Am Coll Cardiol,2005,45(5):712-719.
[6]Sayjili E,Rana OR,Sayjili E,et al.Losartan prevents stretch-induced electrical remodeling in cultured atrial neonatal myocytes[J].Am J Physiol Heart Circ Physiol,2007,292(6):H2898-H2905.
[7]李牧蔚,王宪沛,高传玉,等.替米沙坦对电压依赖性的Kv1.3和Kv1.5通道电流阻断作用的实验研究[J] 中华心血管病杂志, 2009, 37(2):165-168.
[8]Guntekin U, Gunes Y, Tuncer M, et al. .Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients[J].Adv Ther,2008,25(8):775-786.
[9]Schmieder RE,Kjeldsen SE,Julius S,et al.Reduced incidence of new-onset atrial?brillation with angiotensin II receptor blockade: the VALUE trial[J].J Hypertens,2008,26(3):403-411.
[10]Jibrini MB,Molnar J,Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system:A systematic review and meta-analysis[J].Am J Therapeutics,2008,15(1):36-43.